The ratings of three Pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More
- ADVERTISEMENT
- ADVERTISEMENT
The ratings of three Pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More
There's nothing worse than excessive CEO compensation with little to nothing to show for it. We look at three leaders who are simply paid way too much. More
The S&P 500 and the Dow Jones Industrial Average both finished the first quarter of 2013 by setting new all-time highs. More
This week, these five stocks have the best ratings in Earnings Surprises, one of the eight Fundamental Categories on Portfolio Grader. More
This week, these five stocks have the worst ratings in Earnings Surprises, one of the eight Fundamental Categories on Portfolio Grader. More
This week, these ten stocks have the worst year-to-date performance. Each of these also rates an "F" ("strong sell") on Portfolio Grader. Since the beginning of the year, the Nasdaq rose 4.6%, the Dow is up 8.3%, and the S&P has risen 6.9%. More